Synthetic biomimetic matrices with osteoconductivity and osteoinductivity have been developed to regenerate bone tissues. However, whether such systems harbor donor marrow in vivo and support mixed chimerism remains unknown. We devised a strategy to engineer bone tissues with a functional bone marrow (BM) compartment in vivo by using a synthetic biomaterial with spatially differing cues. Specifically, we have developed a synthetic matrix recapitulating the dual-compartment structures by modular assembly of mineralized and nonmineralized macroporous structures. Our results show that these matrices incorporated with BM cells or BM flush transplanted into recipient mice matured into functional bone displaying the cardinal features of both skeletal and hematopoietic compartments similar to native bone tissue. The hematopoietic function of bone tissues was demonstrated by its support for a higher percentage of mixed chimerism compared with i.v. injection and donor hematopoietic cell mobilization in the circulation of nonirradiated recipients. Furthermore, hematopoietic cells sorted from the engineered bone tissues reconstituted the hematopoietic system when transplanted into lethally irradiated secondary recipients. Such engineered bone tissues could potentially be used as ectopic BM surrogates for treatment of nonmalignant BM diseases and as a tool to study hematopoiesis, donor-host cell dynamics, tumor tropism, and hematopoietic cell transplantation.
tissue engineering | regenerative medicine | mixed chimerism | stem cells | bone marrow T ransplantation of hematopoietic stem cells (HSCs) or bone marrow (BM) cells is increasingly being used as a standard care of treatment for diverse life-threatening blood disorders, including hematologic malignancies, immune system disorders, metabolic diseases, hemoglobinopathies, and auto-immune diseases (1) (2) (3) (4) (5) (6) . Successful allogeneic HSC or BM transplantation relies heavily on the ability of the HLA-matched donor cells to replace the recipient's hematopoietic functions by homing and engrafting into the host BM niche (7) (8) (9) . Currently, all transplantations require recipient conditioning, which involves cytoreductive agents and/or irradiation to improve donor cell engraftment (10) (11) (12) . The conditioning provides immunosuppression and allows for donor cells to engraft in the recipient HSC niche (12, 13) . However, such conditioning regimens are often accompanied by short-term and longterm adverse effects in patients (12, (14) (15) (16) ). An extramedullary marrow that acts as a reservoir for donor BM cells by contributing to adequate mixed chimerism, without the need for recipient conditioning, would potentially benefit patients by reducing side effects and the donor cell numbers needed with curative outcomes.
Several studies have shown host-cell-mediated hematopoiesis in ectopic bone tissues (17) (18) (19) (20) (21) (22) (23) (24) (25) . These approaches include implantation of osteoinductive materials like demineralized bone powder (20) , bone shafts (18) , cell-laden synthetic or biological biomaterials (19, (21) (22) (23) (24) (25) (26) in ectopic sites such as s.c. tissue, small bowel mesentery, or subrenal capsule. These studies have demonstrated that engineered ectopic bone tissues can recruit host hematopoietic cells (17) (18) (19) (20) (21) (22) 26) or attract i.v.-administered donor hematopoietic progenitor cells to reconstitute the BM environment (23) (24) (25) 27 ).
HSCs reside in BM in close proximity with calcified endosteal bone and the perivascular niche; the cellular and noncellular components of the niche play a key role in hematopoiesis (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) . Leveraging these understandings, we hypothesize that osteoinductive synthetic scaffolds loaded with hematopoietic cells could result in ectopic bone tissues with hematopoiesis in a spatially confined manner similar to native long-bone tissue. We explored the potential of tissue-engineered ectopic bone tissues with a marrow compartment as a reservoir for donor BM cells and the ability of such a system to establish mixed chimerism in the recipient. To this end, we have developed a biomaterial displaying a dual-compartment structure with an outer osteoinductive mineralized shell encasing either a nonmineralized macroporous inner layer or a hollow core for loading with bone marrow cells (BMC) or bone marrow flush (BMF), respectively. Our findings demonstrate that the outer shell of the implants matured into calcified bone in vivo with an inner hematopoietic compartment that supports long-term hematopoietic maintenance. Furthermore, the donor hematopoietic cells within the engineered bone yielded a higher mixed chimerism in the circulation of recipient mice compared with that of i.v. injections and responded to a hematopoietic stem cell mobilization agent.
Results and Discussion
Development of Monolithic and Dual-Compartment Matrices. Macroporous matrices with interconnected pores were fabricated by poly(methyl methacrylate) templating of poly(ethylene glycol)-diacrylate-co-N-acryloyl 6-aminocaproic acid (A6ACA) (PEGDAco-A6ACA) (SI Appendix, Fig. S1 and SI Experimental Procedures).
Significance
Current bone marrow (BM) or hematopoietic stem cell (HSC) transplantations require recipient conditioning that is accompanied by significant adverse effects in patients. Here, we report engineering of bone tissues with a functional BM compartment in vivo by modular assembly of mineralized and nonmineralized macroporous structures. These engineered bone tissues support maintenance of donor hematopoietic cells, respond to an HSC mobilization agent, and yield higher mixed chimerism in circulation of nonirradiated recipient mice compared with that of intravenous transplantation. Such engineered bone tissues could potentially be used as ectopic BM surrogates to treat various nonmalignant BM diseases and as a tool to study hematopoiesis, donor-host cell dynamics, tumor tropism, and hematopoietic cell transplantation.
Details of the synthesis of precursors as well as formation of macroporous matrices and their mineralization are described elsewhere (38) (39) (40) (41) . The nonmineralized and mineralized matrices were assembled to create a dual-compartment structure with the outer compartment mineralized and the inner compartment either nonmineralized or hollow, emulating the structure of long-bone tissue (SI Appendix, Figs. S1 and S2A and SI Experimental Procedures). In the case of dual-compartment matrices with a nonmineralized macroporous inner compartment, structures with two different inner dimensions (4-mm length × 1.5-mm radius vs. 1-mm length × 0.5-mm radius) were prepared. Characterization of the matrices by scanning electron microscopy (SEM) showed an interconnected porous network with a plate-like morphology of matrix-bound calcium phosphate (CaP) minerals that were confined within the mineralized compartment with no such minerals detected in the inner compartment (SI Appendix, Fig. S2A ). The presence of CaP minerals in the outer compartment was further identified by elemental analysis that revealed a calcium/phosphorus (Ca/P) ratio of 1.38. As determined from the SEM images, the nonmineralized and mineralized macroporous compartments exhibited a pore diameter of 104.6 μm ± 18.9 μm and 82.2 μm ± 15.3 μm in their dried state, respectively (SI Appendix, Fig. S2B ). The pore sizes of the macroporous mineralized and nonmineralized structures were found to be 112.7 μm ± 6.9 μm and 111.1 μm ± 6.8 μm, respectively, in their swollen state (SI Appendix, Fig. S2C ).
Nonmineralized and Mineralized Matrices in the Function of BoneMarrow-Derived Cells. The effects of nonmineralized and mineralized matrices on promoting osteogenic differentiation of mesenchymal stromal cells and maintenance of hematopoietic cells were determined by using monolithic matrices. Consistent with our prior studies involving human stem cells (42) (43) (44) , the mouse mesenchymal stromal cells (mMSCs) cultured within the mineralized matrices underwent osteogenic differentiation in vitro in growth medium lacking any osteogenic-inducing molecules (SI Appendix, Fig. S3 A and B). No such osteogenic differentiation was observed for mMSCs cultured on corresponding nonmineralized matrices. By contrast, the nonmineralized matrices consistently maintained a higher percentage of human CD34-positive cells than mineralized matrices after 14 d of in vitro culture (SI Appendix, Fig. S4 A and B) . In vivo implantation of BMC-loaded monolithic matrices showed significantly higher numbers of long term-HSCs (LT-HSCs) in nonmineralized matrices compared with mineralized matrices (SI Appendix, Fig. S4C ). However, this in vivo finding should be considered noting that the implanted BMC-laden nonmineralized matrices undergo auto-calcification in vivo (calcification observed mainly along the periphery of the implant) mostly due to the presence of 6-aminocaproic acid (A6ACA) moieties that can facilitate mineralization by binding to Ca2 + in the milieu. Previously, we have shown that human embryonic stem cell-loaded nonmineralized PEGDA-co-A6ACA scaffolds in vivo progressed to form spatially distinct bone and fat tissues with calcification and bone tissue formation confined mostly along the periphery (43) .
Spatially Controlled Formation of Bone Tissue Harboring Donor
Hematopoietic Cells. The dual-compartment matrices were seeded with either BMC or BMF at an initial total cell number of ∼5.2 × 10 7 cells (corresponding to ∼5 × 10 7 CD45-positive hematopoietic cells). In the case of BMF, the BM flush was loaded into the hollow core and capped with a disk of the mineralized matrix to confine the flush (SI Appendix, SI Experimental Procedures and Fig. S1 ). Synthetic matrices seeded with BMC or BMF were subcutaneously implanted into congenic mice to test for their ability to form bone tissue with a marrow compartment in a spatially confined manner. (Fig. 1B) , suggesting the maintenance of donor hematopoietic cells by the engineered bone tissue. The gross appearance of the excised implants at 4 wk postimplantation suggests formation of hard tissue with observable vascular networks (SI Appendix, Fig. S5A ). Three-dimensional microcomputed tomography (μCT) showed that implants (BMC-and BMF-laden matrices) that were initially undetectable before implantation (SI Appendix, Fig. S5A ) had progressed to a hard tissue with calcification confined mostly within the outer compartment and with no significant hard tissue formation in the inner compartment for both BMC and BMF groups (SI Appendix, Fig. S5 A and B and Movies S1 and S2). Quantification of the μCT images for bone volume corroborated the above-mentioned observations (SI Appendix, Fig. S5C ). Formation of hard tissues with dual compartments exhibiting differentially cellularized regions and abundance of extracellular matrix was confirmed by hematoxylin and eosin (H&E) staining. The histological analysis revealed a high cell density in the inner compartment for both the BMC and BMF groups, similar to the high cellularity found in native BM (Fig. 1C and SI Appendix, Fig. S5D ). As evident from the H&E staining, the outer compartment of the implanted constructs exhibited woven bone-like structures (Fig. 1C) . To investigate whether osteoclast-like cells are present in the engineered bone tissue, a tartrate-resistant acid phosphatase (TRAP) assay was carried out. Positive TRAP signals were observed in both the BMC and BMF groups in the outer calcified compartment (Fig. 1D) . The sorted TRAP-positive cells were positive for cathepsin K gene expression as shown by cycle threshold value but undetectable in TRAP-negative cells (SI Appendix, Fig. S6A ). Flow cytometric analyses of the outer calcified compartment showed that the majority of CD45/TRAP double-positive cells originated from donor cells whereas some were of host origin (SI Appendix, Fig.  S6B ). Although precursors of osteoclasts reside mostly in the BM (45, 46) , these precursors are also detected in the circulation (47) and likely also contributed to the presence of host TRAP-positive cells in engineered bone. The coexistence of TRAP-positive osteoclast-like cells with osteoblasts implies potential remodeling of the engineered bone (48) (49) (50) . Contrary to TRAP, immunohistochemical staining for perilipin, a marker of adipocytes, was found to be concentrated in the inner compartment of the engineered bone (Fig. 1E ). This is consistent with native marrow because fat is a constituent of bone marrow, but absent in calcified tissues.
Immunohistochemical staining for osteocalcin, an osteoblast matricellular protein, showed higher intensity in the outer compartment compared with the inner compartment at 4 wk (SI Appendix, Fig. S7 A-C) . The intensity of osteocalcin staining decreased as a function of time after 12 wk, which indicates the maturation of the neo-bone tissue (SI Appendix, Fig. S7 D-F) . Osteopontin and bone sialoprotein gene expressions were also up-regulated in the outer compartment (SI Appendix, Fig. S8 A and B) . Furthermore, the presence of collagen, a protein abundant in bone ECM, was also significantly higher in the outer compartment compared with the inner compartment as demonstrated by picrosirius red staining and the mean histogram intensity of the corresponding images (SI Appendix, Fig. S9 A-C) . Because macroporous mineralized matrices are inherently osteoinductive (38, 42) , the accumulated calcification and bone-specific ECM proteins within the mineralized outer compartment could have resulted from the differentiation of osteoprogenitor cells and the build-up of osteoblast-secreted ECM. We have previously shown that the macroporous mineralized materials can contribute to ectopic bone tissue formation through cells recruited from the recipient (38, 51) . The vascularization of the engineered bone was characterized by immunofluorescent staining for CD31 (PECAM1), which shows the presence of vascular endothelial cells in both BMC and BMF groups (SI Appendix, Fig.  S10A ). Flow cytometric analyses of CD31-postive cells further reveal that a similar ratio of donor and host cells contributed to the endothelial cell population of the engineered bones (SI Appendix, Fig. 10B ).
Taken together, the results from μCT and histology showed that both the BMC and BMF implants in vivo matured into dualcompartment structures with cellular and ECM characteristics similar to native bone tissues with a marrow compartment. Unlike prior studies that displayed random calcification at the site of implanted BM (17, 18, 21, 23) , the dual-compartment structure with differential calcification facilitated spatially controlled bone tissue formation confined to the outer compartment with minimal calcification in the inner compartment. The engineered bone exhibiting a dual-compartment structure with an inner marrow compartment harbored by an outer shell of bone resembles the transverse plane of long bones.
Maintenance of Donor and Host Hematopoietic Cells in Engineered
Bone. The maintenance of donor hematopoietic cells within the engineered bone was determined for different host environments including congenic, syngenic, and irradiated mice (SI Appendix, Fig. S11A ). Analysis of the implanted BMC and BMF constructs at 1 d postimplantation showed that the donor cells in irradiated mice had less apoptosis and necrosis than those in nonirradiated congenic recipients (SI Appendix, Fig. S11 B-E) . The donor hematopoietic cells were found in all engineered bone tissues with those in irradiated recipient mice harboring more donor cells over time than nonirradiated recipient mice (SI Appendix, Fig. S11 F and G) . Donor hematopoietic cell numbers in irradiated recipients remained stable over 1-3 mo (SI Appendix, Fig.  S11 F and G) .
Immunofluorescent staining showed the presence of rare CD150 + CD48 − hematopoietic cells within the engineered bone (both BMC and BMF groups) after 4 wk of implantation, suggesting the presence of hematopoietic stem and progenitor cells (HSPCs) ( Fig. 2A) (52) . As expected, engineered bones in irradiated congenic mice contained more LT-HSCs (L Fig. S13B ). Similar findings were also observed with the nonirradiated syngenic recipients (SI Appendix, Fig. S14 A-C) .
The presence of vasculature suggests that cells may migrate between the engineered bone and the host circulation. In addition to donor cells, host hematopoietic cells were also found in the implanted BMC and BMF groups in congenic and syngenic mice (nonirradiated). Similar numbers of host cells, LT-HSCs, ST-HSCs, MPPs, CMPs, and CLPs and frequencies of HSPCs were found in the BMC and BMF groups after 4 wk irrespective of the host environment (syngenic vs. congenic). The number of host cells within the implants increased over time in both congenic (SI Appendix, Fig.  S13 C-F) and syngenic recipients (SI Appendix, Fig. S14 D-F) . Furthermore, host mature T, B, and myeloid cell populations were also found within the engineered bone tissues (both BMC and BMF groups) (SI Appendix, Fig. S13F ).
The recruitment of host cells could either be elicited by the presence of BM cells present in the engineered bone that may secrete abundant chemokines and cytokines (53) or be the result of an immune response to the foreign implant (54) (55) (56) (57) . We believe that the engineered BM is not merely an attractor of immune cells but one that offers a hematopoietic environment as many key populations of the host hematopoietic cell lineages were found within the engineered bone. Furthermore, hematopoietic cells were maintained over 3 mo in engineered bone, which is a considerably longer time than migration and the presence of lymphocytes due to inflammatory responses. We also investigated the colony-forming ability of the hematopoietic cells derived from the BMC and BMF constructs 4 wk postimplantation. The in vitro colony-forming assay showed that the cells derived from the BMC and BMF groups were able to develop into colony-forming units including CFU-GEMM, CFU-GM, and BFU-E (SI Appendix, Fig.  S15 A-C) .
Because the dimensions of the inner compartment of the BMC and BMF groups were different, we determined the effect of the size of the inner compartment on the hematopoietic maintenance. To this end, we assembled BMC constructs with an inner dimension similar to that of BMF constructs, which we denoted BMC-S (SI Appendix, Fig. S16A ). Comparing the ability of BMC-S to support hematopoietic cells with that of BMC groups showed that the total donor hematopoietic cell and LT-HSC numbers were not significantly different between the two implants after 4 wk of implantation (SI Appendix, Fig. S16 B and C).
Donor Chimerism and Hematopoietic Reconstitution. Because the engineered bones are vascularized and maintain hematopoietic lineages in vivo, we looked into whether the hematopoietic cells of the BMC and BMF constructs were functional by investigating the presence of donor cells in circulation. After 4 wk and 24 wk of BMC or BMF construct implantation, peripheral blood was harvested, and the fraction of donor and host hematopoietic cells was analyzed and compared against that of tail-vein injection and/or kidney capsule implantation involving similar cell numbers (Fig. 3A) . Donor cell chimerism was detected in all animals bearing the engineered bones with 3.91 ± 0.69% and 4.11 ± 0.67% for BMC and BMF groups, respectively, compared with 0.66 ± 0.52% for the tail-vein-injected group and 4.58 ± 0.90% for the kidney capsule implantation group after 4 wk. Similar levels of donor cell chimerism were observed 24 wk postimplantation of BMC and BMF groups (Fig. 3B) . These results showed that the engineered bone supports long-term maintenance of the donor marrow cells without recipient conditioning. The number of HSCs within the engineered bone tissues would be a key factor in determining their hematopoietic function, as more cell survival would lead to higher donor cell number and frequency of donor chimerism. Prior studies have shown a positive correlation between the number of transplanted HSPCs or BM cells to the engraftment efficiency in nonmyeloablated recipients (58-61). The modular dual-compartment scaffold offers an enabling screening platform to identify optimal factors (cellular and extracellular components) that support hematopoiesis.
To further validate the hematopoietic function of the engineered bone, the HSPC mobilization agent chemokine (C-X-C motif) receptor 4 (CXCR4) antagonist, AMD 3100, was administered into mice implanted with the BMC-and BMF-laden matrices. The results were compared against mice receiving similar number of cells through tail-vein injection or kidney capsule implantation. Upon administration of AMD 3100, donor cells from both BMC and BMF groups were mobilized into the circulation resulting in a significantly higher number of cells in the peripheral blood than in the basal state (Fig. 3C) . The donor cells in circulation were significantly higher than those of the i.v.-injected group but similar to kidney capsule implantation. This suggests that the functional responsiveness of donor cells, including HSPCs, is mobilized from the engineered bone into the circulation (62, 63) . Flow cytometric analysis did not detect any donor cells within the host BM, suggesting that the presence of donor cells in the circulation directly originated from the engineered bone and not through the host BM. The function of donor hematopoietic cells from engineered bone was further examined by transplanting donor CD45.1 cells along with CD45.2 support (competitor) cells into lethally irradiated CD45.2 mice (Fig. 4A) . Among the BMF and BMC groups, donor myeloid and B and T cells from the BMF groups were found at a higher percentage in the peripheral blood of the recipient CD45.2 mice than those from the BMC group (Fig. 4 B  and C) . Various lineages of donor HSPCs were also found in the recipient BM, wherein BMF-derived cells exhibited a higher reconstitution of HSPCs in the host compared with the BMCderived cells (Fig. 4D ). This could be due to the BM ECM present in BMF groups, which is lacking in the BMC group.
Together, the results showed that the engineered bone with a marrow compartment not only attained a higher donor cell chimerism compared with i.v. injection, but also responded to the HSPC mobilization drug AMD 3100. These attributes could have tremendous implications in translational medicine and suggest that the engineered bone maintains a functional HSC niche with a selective advantage of donor cell survival over i.v. injection. Such easyto-use and cost-effective tissue-engineered bone could potentially be used as HSPC or BM surrogates of allogeneic donor cells as an alternative method for cell transplantation to treat various nonmalignant hematopoietic diseases (64) . This approach could require fewer cell numbers than conventional i.v. injection and prevent the need for recipient conditioning while achieving higher mixed chimerism in recipients of hematopoietic cell transplantation. Moreover, the engineered bone could be applied as a technological platform to understand how individual BM cell populations or ECM affect hematopoietic functions within the marrow compartment during hematopoietic development, homeostasis, aging, and disease.
Experimental Procedures
Detailed methods are described in SI Appendix, SI Experimental Procedures. All experiments were conducted with a sample size of n ≥ 3 and were also independently repeated at least twice.
Synthesis of PEGDA-co-A6ACA Hydrogels and Macroporous Hydrogels. Macroporous poly(ethylene glycol)-diacrylate (PEGDA) (M n = 3.4 kDa)-co-N-acryloyl 6-aminocaproic acid (A6ACA) hydrogels were synthesized as previously described (38) .
Biomineralization of Hydrogels and Macroporous Hydrogels. Biomineralization of the PEGDA-co-A6ACA macroporous hydrogels was carried out as described elsewhere (38) . /BoyJ (CD45.1), and C57BL/6-Tg(UBC-GFP)30Scha/J (Jackson Laboratory) mice were bred in the specific pathogen-free area of the institutional animal facility and maintained in a clean region of the facility during the experiments. Two-to three-month-old mice were used for all of the experiments. All experiments were approved by the Institutional Animal Care and Use Committee of the University of California, San Diego, and were performed in accordance with national and international guidelines for laboratory animal care. BMCs were prepared by repeated pipetting of the BM flush in growth medium to disrupt the cells and ECM. Cells were collected by passing through a cell strainer (40 μm) and centrifuged at 300 × g. On the other hand, the BMFs were prepared without disturbing the whole BM and left intact once it was flushed out. 
